Introduction
Despite substantial progress, much of the genetic variation in schizophrenia susceptibility remains to be attributed. [1] [2] [3] [4] Our recent data suggest a spectrum of risk variation, including rare variants, and a substantial contribution from thousands of common susceptibility variants of small effect. 4 In addition, many of these common variants may also contribute to bipolar disorder but not other common complex disease, which accords with epidemiological support for some genetic overlap between these disorders. 5 Identifying and confirming small genetic effects is likely to be challenging and a substantial barrier to translational research in psychoses.
Investigating genomic data at the level of molecular pathways rather than at individual single-nucleotide polymorphisms (SNPs) is a potentially promising approach. Pathway-based analyses of genomic data may offer several advantages over traditional genetic association analyses: First, by increasing study power if, as has been suggested, the joint action of common variants within pathways have a major role in predisposing to complex genetic disorders. 6 Second, by being robust to the influence that differences in linkage disequilbrium (LD) (for example, between study populations or SNP arrays) may have on identification of associated variants. Third, by providing additional information related to function over and above the statistical SNP genome-wide association study (GWAS) data; that is, implicating a molecular pathway in a disease process may be more biologically informative than interpreting involvement of an anonymous genetic marker.
A number of formal pathway-based analytical methods have been described previously [6] [7] [8] [9] [10] [11] and are reviewed elsewhere. 9, 12 In this study, we used the SNP ratio test (SRT) 10 for the following reasons. The SRT is similar to approaches using methods based on gene set enrichment analysis 9 in that it tests for enrichment of statistically associated SNPs in a pathway using empirical P-values. As the SRT uses all SNPs in the pathway, it can account for situations in which LD, extending beyond the gene of interest, generates false positives at an SNP level. The test is robust to allelic or locus heterogeneity and can capture information from multiple signals at a given locus. As the application of the test is at a pathway rather than at a gene level, this also precludes the need to adjust for gene size. However, all pathway-based methods are limited by the quality of the pathway annotation available and differences in how pathways are defined. The SRT can be applied flexibly to different pathway resources. For this study, we selected only pathways identified in the Kyoto Encyclopaedia of Genes and Genomes (KEGG) database, 13 as these have been experimentally validated. Inevitably, pathways will be enriched for well-studied genes, but in a hypothesis-free test this should not affect the type 1 error rate. For this reason, we did not weight pathways on the basis of previous evidence for involvement in the etiology of schizophrenia or psychosis.
The purpose of this study was to apply a pathwaybased approach to the analysis of GWAS data obtained from two large schizophrenia samples. The initial step was an exploratory analysis in the International Schizophrenia Consortium (ISC) data set. We investigated 212 experimentally validated pathways from the KEGG database for evidence that specific pathways were enriched for SNPs associated with schizophrenia (Pp0.05). Molecular risk pathways identified as meeting this significance threshold were then validated in a large independent data set (Pp0.05). The secondary purpose of this study was to investigate the overlap between validated pathways and bipolar disorder using the same statistical association criteria.
Materials and methods

Participants and genotyping
The ISC was established to promote rapid progress toward the identification of genetic risk factors for schizophrenia. The sample included in the GWAS analysis included 3322 patients with DSM-IV (Diagnostic and Statistical Manual of Mental Disorders-IV) diagnosis of schizophrenia and 3587 controls from the same European populations. SNPs were assayed using the Affymetrix Genome-Wide Human SNP 5.0 and 6.0 arrays (Affymetrix). 3 The analysis provided data on 739 995 SNPs, with a genomic inflation factor of 1.09. Complete details are provided elsewhere. 4 The Genetic Association Information Network (GAIN) is a public-private partnership of the Foundation for the National Institutes of Health. (FNIH) established with the goal of finding genetic causes for common diseases, including schizophrenia. Details on inclusion criteria and participants are available elsewhere. 14, 15 The schizophrenia study (ID phg000013) included 1351 cases and 1378 controls, representing 2601 European ancestry subjects with general research use consent and 219 with schizophrenia and related disorders (schizoaffective) consent. The final data set consisted of 729 454 SNPs. Details of the participating UK cases and controls in the Wellcome Trust Case Control Consortium (WTCCC) bipolar disorder study (n = 4847) are provided in Supplementary material from the original WTCCC paper. 16 The final GWAS analysis included 457 796 SNPs (28 629 SNPs and 196 individuals were excluded as flagged by WTCCC on quality-control grounds).
Data analysis
Pathway analysis methodology. We identified all genic SNPs that mapped to the 212 identified KEGG pathways capturing 4760 genes (Release 48.0, October 2008). First SNPs were linked to genes through the GenBank sequence database using the HUGO (Human Genome Organisation) gene nomenclature, which assigns a unique symbol to every gene. This generated a list of 3 269 098 SNPs known to lie within genes with HUGO gene symbols. An SNP from the GWAS data set was assigned to a gene only if its coordinates lie within the NCBI (National Center for Biotechnology Information) annotated start and stop coordinates of the gene. We also included the region 5 kb upstream and 2 kb downstream of each gene to account for variants in potential promoter regions.
SNP ratio test. In the discovery data set, association analyses were carried out for each SNP in a given pathway using the Armitage trend test. The SRT uses the ratio of nominally significant (P < 0.05) to nonsignificant SNPs for each pathway. An empirical P-value is generated for each pathway by comparing this ratio with ratios based on simulated data sets ( Figure 1 ).
These data sets were simulated by randomizing the case-control status of individuals in our original data set 1000 times, and then by repeating the association analysis. For each simulation, we take the M most significant SNPs, where M corresponds to the number of SNPs below the cutoff used in the original data set, for example, P < 0.05. The use of M, rather than reapplying the P-value threshold should prevent any inflation in empirically significant pathways due to an excess of false-positive SNPs in the original GWAS (due to, for example, genotyping error or other bias). Thereafter, we counted the number of times a simulated ratio was higher than the original ratio. We did this for each pathway, thus correcting for spurious enrichment of significant SNPs due to factors such as LD. Further details on SRT methodology are provided in the study by O'Dushlaine et al.
(2009).
Pathways that provided significant evidence (P < 0.05) for enrichment of associated SNPs, were than tested using the same approach in the validation data set. Finally, we tested the significant pathways identified in schizophrenia in the WTCCC bipolar disorder data set. All file manipulations were carried out using PERL within a UNIX framework (UNIX). Statistical analyses were conducted using STATA 10 (STATA).
Results
Pathway analysis results
Of the 212 KEGG pathways examined in the ISC data set, 47 had significant enrichment of associated SNPs when compared with simulated data sets (Table 1; complete pathway details are provided in Supplementary Table 1 ). This represented more than what we expected by chance (n = B11). In all, 5 of these 47 pathways were associated in the GAIN schizophrenia sample: cell adhesion molecule (CAM) (hsa04514) (P = 0.001); cell cycle (hsa04110) (P = 0.015); vesicular trafficking (SNARE) (hsa04130) (P = 0.016); tight junction (hsa04530) (P = 0.03) and glycan structures biosynthesis 1 (hsa01030) (P = 0.03) pathways. Only the CAM pathway exceeded a conservative correction, assuming independence, for the number of pathways taken to the replication phase. Interestingly, the CAM pathway was also significantly associated in the bipolar disorder data set (P = 0.026). However, pathways are not independent (for example, CAM and tight junction overlap at a molecular level and are involved in the same functions) and genes may be involved in multiple pathways. We would expect only two of the five schizophrenia pathways to be nominally significant in the GAIN data set by chance with an a of 0.05 for the empirical P-value. An exploratory analysis of the other four pathways indicated additional support for glycan structures biosynthesis 1 (P = 0.0009) and tight junction (P = 0.015) pathways in bipolar disorder (Table 1) . We did not observe the same replication across the six nonpsychiatric diseases in the WTCCC. 16 The results for all tested pathways and on specific genes contributing to the significant pathway findings are provided as Supplementary Information.
Implicated genes in schizophrenia risk pathways
We next examined where the SNP signals were coming from in the different data sets. Details in the overlap at SNP level between the schizophrenia data sets are specifically provided in Supplementary Table 3 . The most significant finding in the GAIN replication set was for the CAM pathway, in which there was a substantial enrichment for association in genes involved in neuronal functioning (Supplementary Figure 2) . In all, 28 genes, of 110 contributing to the analysis, had significantly associated SNPs in both data sets and 14 SNPs across 6 of these genes (CDH4, GLG1, NRXN1, CNTN1, HLA-DQA2 and PDCD1LG2) shared common risk alleles in both data sets.
For the tight junction pathway, 27 of 128 genes had significantly associated SNPs in both schizophrenia data sets (Supplementary Figure 3) . Nine SNPs across eight genes (CDC42, CTNNA2, HCLS1, HRAS, PRKCH, MYH11, MYH15 and PARD3) shared common risk alleles (Supplementary Table 2 ).
In the glycan structures biosynthesis 1 pathway, 30 of 111 represented genes were associated in both samples, and 6 SNPs across 5 genes (MAN2A1, GALNT2, GALNT13, OGT and XYLT1) shared common risk alleles (Supplementary Figures 6a-c and Table 1 ). For the SNARE pathway, 6 of 36 genes had significantly associated SNPs in both schizophrenia data sets with two genes attributed to the same SNPs (Supplementary Figure 5) . All 12 significantly associated SNPs in these two genes for both data sets (STX18 and TSNARE1) shared common risk alleles (see Supplementary Table 2 ). The finding for the cell cycle pathway is driven entirely by multiple SNPs in the same gene (MAD1L1) sharing the same risk alleles in both data sets (Supplementary Figure 4) . 
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Gene overlap between schizophrenia and bipolar disorder We were interested in establishing whether the location where molecular pathways overlapped between schizophrenia and bipolar disorder represented the effect of the same key genes. We examined overlap at a gene level between ISC schizophrenia and WTCCC bipolar samples. For the CAM pathway, 49 genes had at least 1 significant SNP in ISC and 22 of these had significant SNPs in WTCCC; for the tight junction pathway, 47 genes had at least 1 significant SNP in ISC and 16 of these genes were replicated; and for the N-glycan biosynthesis pathway, 50 genes had at least 1 significant SNP in ISC and 24 of these were replicated. This suggests a substantial overlap in key genes in both disorders. However, there was less concurrence at the level of identified risk SNPs and alleles between the disorders. For example, in the CAM pathway, nine genes had the same risk SNPs, including CDH4 (Supplementary Table 2 ). For the tight junction pathway, seven genes had the same risk SNPs, including PRKCH, CTNNA2 and MYH15. In the glycan structures biosynthesis 1 pathway, seven genes shared common risk SNPs at seven genes, including MAN2A1.
Discussion
We report a genomic pathway analysis of psychosis capturing 212 experimentally validated molecular pathways using discovery (ISC) and validation (GAIN) data sets. In the discovery data set, we identified evidence for the involvement of a relatively large number of pathways (47 of 212 tested). Five of these pathways were replicated in the replication sample, one of these (CAM) survived conservative multiple testing correction. This sample may have been underpowered to detect more modest effects; a hypothesis that can be directly tested with the imminent availability of larger GWAS data sets, for example, through the Psychiatric GWAS Consortium. 17 Three of the five-CAM, tight junction and SNARE-are involved in processes critical to neurodevelopment and synaptic function. Genes involved in all three have previously been implicated in schizophrenia susceptibility. There is a significant overlap between the CAM and tight junction pathways and both are relevant to synaptic formation and neurotransmission at glutamatergic and GABAergic synapses. 18 There is substantial evidence to support their involvement in cognitive and neuropsychiatric disorders. Genes involved in each of these pathways have been implicated in genetic disorders, which affect cognition (see the Genes to Cognition Database). 19 Interestingly, a recent autism study reported the involvement of similar neuronal cell adhesion pathways. 20 A key issue is whether the same genes are involved across neuropsychiatric disorders. Taking the comparison between schizophrenia and bipolar disorder into account, we identified a substantial overlap in nominally associated SNPs between the schizophrenia (ISC) and bipolar disorder (WTCCC) data sets. This suggests that certain genes may be critical in altering pathway function.
Several of the genes identified as contributing to risk pathways had previously been identified by genetic association or studies of copy number variation in schizophrenia or other neuropsychiatric disorder phenotypes (https://slep.unc.edu/evidence/). Of these, a number had first been reported in the autism literature. We identified shared risk alleles in both schizophrenia samples at SNPs rs9309200 and rs1915220 at NRXN1 (OMIM: 600565). Disruption of NRXN1 has been reported as a risk factor for both schizophrenia [21] [22] [23] and autism. 24, 25 Axonal neurexins form transynaptic complexes with neuroligins on dendrites and are required for the formation of synaptic contacts and for efficient neurotransmission, including maintaining normal postsynaptic NMDA receptor function. A significant association involving the gene CNTNAP2 (OMIM: 604569) was detected in all three psychosis samples. CNTNAP2 is a neurexin superfamily member, which is part of a neurogenetic pathway that is disturbed in different forms of Abbreviations: GAIN, Genetic Association Information Network; ISC, International Schizophrenia Consortium; n, number of nonsignificant SNPs in pathway; P, empirical P-value from comparing ratio of significant to nonsignificant SNPs with ratios in simulated data sets; s, number of significant SNPs in pathway; SNP, single-nucleotide polymorphism; WTCCC, Wellcome Trust Case Control Consortium.
Genetic pathway analysis in psychotic disorders C O'Dushlaine et al language impairment 26 and autism. [27] [28] [29] Friedman et al. 30 have reported genomic deletions of varying sizes involving CNTNAP2 in three nonrelated patients with schizophrenia and epilepsy but not in 512 healthy controls.
Neurexin directly interacts with the cytoskeleton membrane scaffolding protein CASK (OMIM: 300171), which contains associated SNPs in both schizophrenia data sets. Part of the tight junction gene pathway in KEGG; CASK may have a role in synaptic plasticity by coupling synaptic vesicle exocytosis to neuronal cell adhesion. 31, 32 Tight junctions are composed of at least three types of transmembrane proteins-occludin, claudin and junctional adhesion molecules-and a cytoplasmic region containing three large protein complexes, the ZO protein complex, the CRB3-Pals1-PATJ protein complex and the PAR-3-aPKC-PAR6 complex. Transmembrane elements mediate cell adhesion and are believed to constitute both intracellular and paracellular diffusion barriers. The CRB3 and PAR transmembrane complexes are involved in the maintenance of cell polarity, and the ZO cytoplasmic complexes organize coupling with other cytoplasmic proteins and to actin microfilaments. We identified a significant enrichment of associated SNPs in genes involving the PAR complex (CDC42 (OMIM: 116952); PAR3 (OMIM: 606745); PAR6 (OMIM: 607484) and PRKCZ (OMIM: 176982)). The PAR complex establishes cell polarity for myelination 33 and for normal dendritic spine development. 34 Recent evidence suggests that CDC42 may have a critical role in DISC-1 related cell migration through interaction with the gene NUDEL.
35
Reduced expression of CDC42 has previously been shown in the dorsolateral prefrontal cortex of subjects with schizophrenia and this was correlated with decreased dendritic spine density in schizophrenia. 36 Incidentally, GSK3B (OMIM: 605004) which is also modulated by DISC-1, is part of the cell cycle pathway, although not directly contributing to susceptibility in this study. 37 The third pathway identified in all three samples involved carbohydrate structures attached to glycolipids, glycoproteins and proteoglycans. These are known to have a critical role in many biological processes, including cell adhesion during development, immune and inflammatory response, molecular trafficking, signal transduction and endocytosis. 38 In mouse models, regulation of glycan binding is required for most of the physiological functions of neuronal cell adhesion molecules, including brain morphogenesis, axonal trafficking and higher cognitive functioning. 39, 40 The diversity of glycan functions is matched by a potentially vast array of hundreds, if not thousands, of potential structures. None of the overlapping risk alleles identified by this study map to genes previously implicated in psychosis. In fact, cases wherein these genes have been linked to human disease previously have been associated with connective tissue disorders (for example, MAN2A1 (OMIM: 154582), CHST3 (OMIM: 603799), XYLT1 (OMIM: 608124)) or lipid metabolism (GALNT2). 41 Pathway information should not be taken at face value; it is important to examine the gene results. For example, inspection of the cell cycle pathway result indicated that this association was driven by the MAD1L1 gene, thus implicating the gene and not the pathway. Potential confounds in considering these data are that the methodology may be susceptible to bias in LD in the case group, or that the data may reflect increased gene size or greater marker density in the pathways enriched for association. We correct for potential LD bias by randomizing case-control status, but maintaining LD structure and repeating association tests to create a distribution of ratios (N = 1000 simulations). This process retains the existing LD structure, giving a background estimate. Spurious associations arising from LD would lie within this background range. We found no evidence for increased gene size or greater SNP density for associated versus nonassociated pathways (MannWhitney P = 0.07, n = 5 replicated pathways). However, we note that the significance of a pathway is somewhat reliant on the existence of a minimum number of SNPs (B20), which, by extension, relates to factors such as average gene length (Supplementary Figure 2) . In particular, if a pathway has a paucity of SNPs, the likelihood of significant SNPs from a given simulation mapping to this pathway is reduced. Thus, poorly 'covered' pathways are difficult to test, a limitation for GWAS in general (Supplementary Figure 2) .
By selecting only experimentally validated pathways, we restricted the number of genes included in this analysis. Incorporating other pathway tools to expand the number of genes captured in the followup of these findings may be useful, although there is a lack of consensus across methods as to how pathways are defined and classified. 42 It is worth noting that the SRT does not correct for multiple testing at a pathway level. This is nontrivial because molecular processes can involve more than one pathway, hence our strategy of replicating the exploratory findings. However, the multiplicity problem is greatly reduced by this approach relative to an SNP-level analysis.
This study implicates pathways involved in neuronal cell adhesion and synaptic function in molecular susceptibility to psychosis. Intriguingly, there is now significant convergence using different genetic analyses on key molecules in these pathways being broadly involved in neurodevelopmental disorders, including psychosis, autism and language disorders. This may be of significant diagnostic and therapeutic importance. Our study identified multiply associated SNPs at several genes, for example, MAD1L1, CDH4 and TSNARE1. Examining LD relationships at these loci suggests that this may represent multiple signals. For example, the 26 associated SNPs at MAD1L1 can be captured by 6 tagging SNPs. More definitive interpretation of individual loci will require additional resequencing. For further investigation of these pathways in independent data sets, we would propose testing a model that expands promoter and other regulatory regions, that includes investigation of other genetic models (for example, epistasis), that allows estimation of effect size/predictive value and that investigates whether the pathways identified are associated with age at onset and course of disease. Twinned with ongoing targeted DNA-sequencing studies, this may be informative in quantifying and specifying the impact of discrete molecular pathways on different clinical outcomes. Further functional work is required in particular to investigate neuronal cell adhesion and membrane scaffolding, given the growing convergence across studies of neurodevelopmental disorders on these mechanisms.
